Results 1 to 10 of about 45,662 (251)
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial [PDF]
European Journal of Heart Failure, 2016 AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Orly Vardeny +2 more
exaly +3 more sources
Efficacy and safety of sacubitril/valsartan in end-stage renal disease patients with heart failure: a review [PDF]
Annals of MedicinePurpose End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and ...
Peiyun Li, Yupei Li, Ling Zhang
doaj +2 more sources
Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial [PDF]
Nature CommunicationsDiffuse interstitial fibrosis is associated with adverse outcomes in hypertensive heart disease and may be reversible. Sacubitril/valsartan could offer greater anti-fibrotic effects than valsartan alone.
Vivian Lee +15 more
doaj +2 more sources
Sacubitril/valsartan preserves kidney function in rats with cardiorenal syndrome after myocardial infarction. [PDF]
PLoS ONERenal dysfunction in heart failure increases mortality, limits treatment options and blunts responses to therapy. Angiotensin receptor-blocker and neprilysin inhibitors (ARNI) may preserve renal function by modulating both the renin-angiotensin ...
Kaja Knudsen Bergo +11 more
doaj +2 more sources
Prescription Patterns of Sacubitril/Valsartan in an Outpatient Population Diagnosed with Heart Failure with Reduced Ejection Fraction After a Recent Hospitalization [PDF]
EpidemiologiaBackground: Sacubitril/Valsartan is a first-line treatment for heart failure with reduced ejection fraction (HFrEF) according to international guidelines.
Dimitri Roustan +2 more
doaj +2 more sources
Molecules, 2021 The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with cardioprotective properties.
Pema Raj +6 more
doaj +1 more source
Cardiovascular Diabetology, 2022 Background Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial.
Magnus O. Wijkman +14 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2023 IntroductionIn 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from ...
Pei Yang +7 more
doaj +1 more source
Scientific Reports, 2021 Left ventricular remodeling due to pressure overload is associated with poor prognosis. Sacubitril/valsartan is the first-in-class Angiotensin Receptor Neprilysin Inhibitor and has been demonstrated to have superior beneficial effects in the settings of ...
Xiaofei Li +4 more
doaj +1 more source
Frontiers in Public Health, 2022 BackgroundSacubitril-valsartan was recommended for heart failure (HF) and proven cost-effective in HF. Recently, sacubitril-valsartan has been recommended to treat hypertension by the Chinese expert consensus. The cost utility of sacubitril-valsartan for
Yake Lou +4 more
doaj +1 more source